A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

Abstract Introduction Ivacaftor (IVA) has been shown to change the trajectory of cystic fibrosis (CF) disease progression by slowing the rate of lung function decline in clinical studies. Long-term real-world data help to confirm the durability of this response. Methods This non-interventional, long...

Full description

Saved in:
Bibliographic Details
Main Authors: Christian Merlo, Teja Thorat, Lisa J. McGarry, Christina V. Scirica, Maral DerSarkissian, Catherine Nguyen, Yuqian M. Gu, Aruna Muthukumar, Joe Healy, Jaime L. Rubin, M. Alan Brookhart
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-09-01
Series:Pulmonary Therapy
Subjects:
CFTR modulator
Cystic fibrosis
Disease trajectory
Ivacaftor
Longitudinal study
Lung function decline
Online Access:https://doi.org/10.1007/s41030-024-00269-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s41030-024-00269-9

Similar Items